Sarepta Therapeutics Inc (SRPT)
Debt-to-assets ratio
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Long-term debt | US$ in thousands | — | — | — | — | — |
Total assets | US$ in thousands | 3,963,170 | 3,264,580 | 3,128,370 | 3,147,970 | 2,984,720 |
Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-assets ratio = Long-term debt ÷ Total assets
= $—K ÷ $3,963,170K
= 0.00
The debt-to-assets ratio of Sarepta Therapeutics Inc has consistently remained at 0.00 from December 31, 2020, all the way through December 31, 2024. This indicates that the company has had no debt in relation to its total assets over the specified period. A low or zero debt-to-assets ratio can signify a strong financial position and lower financial risk for the company. Sarepta Therapeutics' ability to maintain a debt-free status suggests that it may be relying more on equity financing or other sources of funding to support its operations and growth initiatives.
Peer comparison
Dec 31, 2024
Company name
Symbol
Debt-to-assets ratio
Sarepta Therapeutics Inc
SRPT
0.00
Abbott Laboratories
ABT
0.00
AbbVie Inc
ABBV
0.00
ACADIA Pharmaceuticals Inc
ACAD
0.00
Alkermes Plc
ALKS
0.00
Amphastar P
AMPH
0.39
ANI Pharmaceuticals Inc
ANIP
0.00
Arcus Biosciences Inc
RCUS
0.00
Biomarin Pharmaceutical Inc
BMRN
0.09
Bristol-Myers Squibb Company
BMY
0.51
Catalyst Pharmaceuticals Inc
CPRX
0.00